Treatment of Premature Ejaculation (PE)

Definition & Classification

PE is defined as ejaculation that occurs prior to or within approximately 1 minute of vaginal penetration (in the majority of lifelong cases within 30-60 seconds), with inability to delay ejaculation on nearly all penetrations, and resulting in negative personal consequences such as distress, frustration, or avoidance of sexual intimacy (ISSM definition).

Four subtypes are recognized:

Lifelong (primary) PE - present from first sexual encounter; likely neurobiologic basis
Acquired (secondary) PE - develops after a period of normal ejaculation; often linked to underlying medical cause (e.g., erectile dysfunction, hyperthyroidism, prostatitis)
Natural variable PE - occasional early ejaculation; normal variation, not a disorder
Subjective PE - perceived PE with objectively normal IELT (usually 2-6 min); psycho-cultural basis

General Approach

Treatment is tailored to PE subtype:

Lifelong PE: pharmacotherapy (daily or on-demand SSRIs/topical agents) alone or combined with psychosexual therapy
Acquired PE: treat the underlying cause first (e.g., ED pharmacotherapy, thyroid correction), combined with PE pharmacotherapy
Variable/Subjective PE: psychosexual education and couple psychotherapy are primary

Partner involvement, when possible, enhances outcomes by improving confidence, reducing performance anxiety, and fostering better sexual communication. (Campbell-Walsh Wein Urology)

1. Psychosexual Therapy

All men with PE should receive basic psychosexual education:

Psychoeducation: realistic norms for IELT, dispelling myths
Behavioral techniques: the stop-start technique (Semans, 1956) and the squeeze technique (Masters & Johnson) - patient or partner manually stimulates until impending ejaculation, then pauses or applies pressure to the glans until urge subsides
Sensate focus exercises
Reduction of performance anxiety and modification of maladaptive sexual scripts
Extending the couple's sexual repertoire

Evidence for behavioral therapy alone is limited, but CBT combined with SSRIs shows significantly better outcomes than either alone (PMID: 39492575 - 2025 meta-analysis).

2. Pharmacologic Treatment

A. Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs block axonal serotonin reuptake, enhancing 5-HT neurotransmission and delaying ejaculation via postsynaptic 5-HT receptor stimulation.

Drug	Dose	Regimen	Notes
Dapoxetine	30 mg or 60 mg	On-demand, 1-2 hrs before	Only SSRI specifically approved for PE (>50 countries; not FDA approved in US). 2.5-3x IELT increase vs. placebo from first dose
Paroxetine	10-40 mg/day	Daily (off-label)	Most potent ejaculation delay of daily SSRIs; ~8.8x IELT fold increase
Sertraline	25-200 mg/day	Daily or on-demand (off-label)	Good tolerability
Fluoxetine	20-40 mg/day	Daily (off-label)	Slower onset due to long half-life
Citalopram	20-40 mg/day	Daily (off-label)	Moderate efficacy
Clomipramine	12.5-50 mg	Daily or on-demand (off-label)	TCA; also effective but more side effects

Daily vs. on-demand: Daily dosing generally produces greater IELT prolongation. On-demand dosing (taken 3-6 hours before intercourse for most SSRIs, or 1-2 hrs for dapoxetine) is preferred by many patients for convenience. Combining low-dose daily SSRI with on-demand dosing may improve outcomes further.

Side effects: Nausea, diarrhea, headache, dizziness, insomnia, fatigue, reduced libido, anorgasmia. Rare: serotonin syndrome, suicidal ideation (especially in younger patients).

A 2025 umbrella review of meta-analyses confirmed SSRIs (especially paroxetine and dapoxetine) as the most effective pharmacological treatments, with topical anesthetics and tramadol as additional options (PMID: 40326158).

B. Topical Local Anesthetics

The oldest pharmacological treatment for PE. Reduce glans penis hypersensitivity.

Lidocaine/prilocaine cream or spray (e.g., EMLA cream, Promescent spray): applied to the glans 20-30 minutes before intercourse; a condom should be worn to avoid partner numbness and absorption issues
Benzocaine: available OTC in some countries
SS-cream (a multi-herbal topical): studied in RCTs; delays ejaculation via local desensitization

Topical agents are effective with minimal systemic absorption. They are especially useful for men who prefer non-systemic treatment or cannot tolerate SSRIs.

C. Tramadol

Weak opioid agonist and monoamine reuptake inhibitor
On-demand tramadol (25-50 mg, 2 hrs before) shows modest to good IELT prolongation in RCTs
Off-label use; risk of dependence, dizziness, nausea limits routine recommendation
Not a first-line agent; used when SSRIs and topical agents are inadequate

D. PDE5 Inhibitors (Sildenafil, Tadalafil, Vardenafil)

Not directly effective for PE in men with normal erectile function
Most beneficial in men with comorbid ED and PE - treating the ED component reduces performance anxiety and the tendency to ejaculate quickly
Some evidence that PDE5Is combined with SSRIs are more effective than SSRIs alone in this population

E. Alpha-Adrenergic Blockers

Agents such as alfuzosin or terazosin have been studied
Modest evidence; not a standard first-line option
May be used in acquired PE associated with lower urinary tract symptoms or prostatitis

F. Agents with Insufficient Evidence

Botulinum toxin-A: A 2025 meta-analysis (PMID: 39870913) concluded it is ineffective for PE treatment
Tramadol combined with dapoxetine: limited data

3. Combination Therapy

Pharmacotherapy + psychosexual therapy: superior to either alone. A 2025 meta-analysis (PMID: 41020367) found dapoxetine combined with behavioral/psychosexual approaches significantly more effective for lifelong PE
SSRI + topical anesthetic: can be used together
SSRI + PDE5 inhibitor: for men with comorbid PE and ED

4. Treatment of Underlying Causes (Acquired PE)

Cause	Treatment
Erectile dysfunction	PDE5 inhibitors
Hyperthyroidism	Thyroid normalization (50% PE prevalence falls to 15% after treatment)
Chronic prostatitis	Antibiotics / anti-inflammatory agents
Relationship/psychological issues	Couples therapy, CBT

Summary Algorithm

PE confirmed?
    ├─ Lifelong PE → SSRIs (dapoxetine on-demand, or daily paroxetine/sertraline)
    │                ± topical anesthetic ± psychosexual therapy
    ├─ Acquired PE → Treat underlying cause first
    │                Add SSRI or topical agent as needed
    ├─ Variable PE → Psychoeducation + behavioral techniques
    └─ Subjective PE → CBT, reassurance, couples therapy

Key sources:

Campbell-Walsh Wein Urology, Chapter 71 (ISSM guidelines, pharmacotherapy evidence)
Textbook of Family Medicine 9e, Chapter 40
2025 umbrella review of pharmacological treatments, PMID 40326158
2025 meta-analysis: dapoxetine + behavioral therapy, PMID 41020367
2025 meta-analysis: CBT + SSRIs, PMID 39492575
2025 meta-analysis: Botulinum toxin-A ineffective, PMID 39870913

This is a shared conversation. Sign in to Orris to start your own chat.